BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

825 related articles for article (PubMed ID: 17383089)

  • 1. Oncolytic viruses in cancer therapy.
    Vähä-Koskela MJ; Heikkilä JE; Hinkkanen AE
    Cancer Lett; 2007 Sep; 254(2):178-216. PubMed ID: 17383089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mathematical model of oncolytic virotherapy with time delay.
    Wang ZZ; Guo ZM; Smith H
    Math Biosci Eng; 2019 Mar; 16(4):1836-1860. PubMed ID: 31137188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategy of Cancer Targeting Gene-Viro-Therapy (CTGVT) a trend in both cancer gene therapy and cancer virotherapy.
    Liu XY; Li HG; Zhang KJ; Gu JF
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1761-7. PubMed ID: 21740358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advance in herpes simplex viruses for cancer therapy.
    Liu S; Dai M; You L; Zhao Y
    Sci China Life Sci; 2013 Apr; 56(4):298-305. PubMed ID: 23564184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Going viral: a review of replication-selective oncolytic adenoviruses.
    Larson C; Oronsky B; Scicinski J; Fanger GR; Stirn M; Oronsky A; Reid TR
    Oncotarget; 2015 Aug; 6(24):19976-89. PubMed ID: 26280277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted oncolytic herpes simplex viruses for aggressive cancers.
    Wong J; Lee C; Zhang K; Rennie PS; Jia W
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1786-94. PubMed ID: 21740360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic viruses in the treatment of cancer: a review of current strategies.
    Zeyaullah M; Patro M; Ahmad I; Ibraheem K; Sultan P; Nehal M; Ali A
    Pathol Oncol Res; 2012 Oct; 18(4):771-81. PubMed ID: 22714538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ReVOLT: radiation-enhanced viral oncolytic therapy.
    Advani SJ; Mezhir JJ; Roizman B; Weichselbaum RR
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):637-46. PubMed ID: 17011442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent clinical experience with oncolytic viruses.
    Donnelly OG; Errington-Mais F; Prestwich R; Harrington K; Pandha H; Vile R; Melcher AA
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1834-41. PubMed ID: 21740364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introduction to Oncolytic Virotherapy.
    Engeland CE; Bell JC
    Methods Mol Biol; 2020; 2058():1-6. PubMed ID: 31486028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic viruses targeting tumor stem cells.
    Chiocca EA; Blair D; Mufson RA
    Cancer Res; 2014 Jul; 74(13):3396-8. PubMed ID: 24753541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational modeling approaches to studying the dynamics of oncolytic viruses.
    Wodarz D
    Math Biosci Eng; 2013 Jun; 10(3):939-57. PubMed ID: 23906157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of virotherapy for effective tumor treatment.
    Garcia-Aragoncillo E; Hernandez-Alcoceba R
    Curr Opin Mol Ther; 2010 Aug; 12(4):403-11. PubMed ID: 20677091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer gene therapy with oncolytic adenoviruses.
    Guse K; Hemminki A
    J BUON; 2009 Sep; 14 Suppl 1():S7-15. PubMed ID: 19785073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical development of oncolytic viruses in China.
    Liang M
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1852-7. PubMed ID: 21740357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic Virotherapy by HSV.
    Watanabe D; Goshima F
    Adv Exp Med Biol; 2018; 1045():63-84. PubMed ID: 29896663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Permissiveness of human cancer cells to oncolytic bovine herpesvirus 1 is mediated in part by KRAS activity.
    Cuddington BP; Mossman KL
    J Virol; 2014 Jun; 88(12):6885-95. PubMed ID: 24696490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. United virus: the oncolytic tag-team against cancer!
    Le Boeuf F; Bell JC
    Cytokine Growth Factor Rev; 2010; 21(2-3):205-11. PubMed ID: 20227326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anatomical and physical barriers to tumor targeting with oncolytic adenoviruses in vivo.
    Strauss R; Lieber A
    Curr Opin Mol Ther; 2009 Oct; 11(5):513-22. PubMed ID: 19806499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The replicability of oncolytic virus: defining conditions in tumor virotherapy.
    Tian JP
    Math Biosci Eng; 2011 Jul; 8(3):841-60. PubMed ID: 21675814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.